Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates
Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their pipelines on the most promising candidates. For Sana, that means halting work on a…